학술논문
Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering
Document Type
Article
Source
In Diabetes & Metabolic Syndrome: Clinical Research & Reviews November 2017 11 Supplement 1:S91-S97
Subject
Language
ISSN
1871-4021